Myasthenia Gravis Disease Market to Grow at a CAGR of 10.8% During 2018–2026: Grifols S.A., Novartis AG, Shire Plc, Hoffmann-La Roche AG, Alexion Pharmaceutical
Myasthenia gravis disease is a neuromuscular ailment that causes the weakness of skeletal muscles, that are used for body movement. MG Disease is generally caused by an autoimmune disease when communication between muscles and nerve cells becomes impaired. According to the Myasthenia Gravis Foundation of America, MG is relatively rare condition that affects approximately 14 to 20 out of every 100,000 people in the United States.
View full press release